ACC: Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients

[cafead]

via Eying a potential blockbuster, Bayer has been busy making the case for its new kidney disease launch Kerendia since the med won approval last summer. Now, the company is touting a pooled dataset showing a reduction in cardio and kidney events for high-risk patients.

article source